It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Adipose tissue (AT) associated cytokines are involved in the development of chronic low-grade inflammation in obese individuals. IL-2, a pleiotropic cytokine, contributes to immune alterations during inflammation. However, the interaction between AT-IL-2 and other inflammatory biomolecules in obesity remains elusive. We investigated whether AT-IL-2 expression was associated with markers of inflammation and insulin resistance in overweight/obese individuals. Subcutaneous fat tissues were collected from 56 individuals (lean/overweight/obese) for RNA extraction. IL-2 and inflammatory mediators were quantified by qRT-PCR and immunohistochemistry. CRP was measured by ELISA. AT-IL-2 expression was higher in obese compared with lean individuals (P < 0.021) and correlated with BMI. IL-2 correlated with interleukins IL-8 and IL-12A (r = 0.333–0.481; p = 0.0001–0.029); as well as with chemokines and their receptors including CCL5, CCL19, CCR2 and CCR5 (r = 0.538–0.677; p < 0.0001). Moreover, IL-2 correlated with toll-like receptors (TLR2, TLR8, TLR10), interferon regulatory factor 5 (IRF5) and cluster of differentiation CD11c (r = 0.282–0.357; p < 0.039). Notably, IL-2 was associated positively with fasting blood glucose (FBG), HbA1c, TGL and CRP (r ≥ 0.423;P ≤ 0.007). In multiple regression analysis, IL-2 is an independent predictor of IL-8, IL-12A, TLR10, TGL and HbA1c. Overall, our data demonstrate that increased expression of the AT-IL-2, in obesity, may represent a novel biomarker for progression of metabolic inflammation and insulin-resistance.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Dasman Diabetes Institute, Immunology and Microbiology Department, Kuwait City, Kuwait (GRID:grid.452356.3) (ISNI:0000 0004 0518 1285)
2 Dasman Diabetes Institute, Animal and Imaging Core Facilities, Kuwait City, Kuwait (GRID:grid.452356.3) (ISNI:0000 0004 0518 1285); Dasman Diabetes Institute, Genetics and Bioinformatics, Kuwait City, Kuwait (GRID:grid.452356.3) (ISNI:0000 0004 0518 1285)
3 Dasman Diabetes Institute, Immunology and Microbiology Department, Kuwait City, Kuwait (GRID:grid.452356.3) (ISNI:0000 0004 0518 1285); Ministry of Health, Immunology Department, Kuwait City, Kuwait (GRID:grid.415706.1) (ISNI:0000 0004 0637 2112)
4 Dasman Diabetes Institute, Animal and Imaging Core Facilities, Kuwait City, Kuwait (GRID:grid.452356.3) (ISNI:0000 0004 0518 1285)
5 Dasman Diabetes Institute, Medical Division, Kuwait City, Kuwait (GRID:grid.452356.3) (ISNI:0000 0004 0518 1285)
6 Dasman Diabetes Institute, Genetics and Bioinformatics, Kuwait City, Kuwait (GRID:grid.452356.3) (ISNI:0000 0004 0518 1285)